Pulmonary Hypertension Associated with Interstitial Lung Disease
Conditions
Brief summary
Percent change from baseline in PVR assessed at estimated peak exposure at Week 16 (%ΔPVR16) by right heart catheterization (RHC)
Detailed description
1. Change in 6MWD from baseline measured at estimated peak exposure at Week 16 using the 6-Minute Walk Test (6MWT), 2. Change from baseline in NT-proBNP at Week 16
Interventions
Sponsors
Pulmovant Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change from baseline in PVR assessed at estimated peak exposure at Week 16 (%ΔPVR16) by right heart catheterization (RHC) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in 6MWD from baseline measured at estimated peak exposure at Week 16 using the 6-Minute Walk Test (6MWT), 2. Change from baseline in NT-proBNP at Week 16 | — |
Countries
Belgium, Czechia, France, Germany, Italy, Latvia, Netherlands, Poland, Spain
Outcome results
None listed